Operating Cash Flow
Regeneron Pharmaceuticals Operating Cash Flow decreased by 7.8% to $1.08B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 3.2%, from $1.05B to $1.08B. Over 4 years (FY 2021 to FY 2025), Operating Cash Flow shows a downward trend with a -8.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Consistently high operating cash flow indicates a healthy, self-sustaining business capable of funding its own growth and returning capital to shareholders.
Detailed definition
Net cash from operating activities measures the total amount of cash generated by a company's core business operations....
Peer comparison
Investors often compare this to capital expenditures to calculate Free Cash Flow, a primary valuation metric for mature tech giants.
net_cash_from_operatingHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $626.70M | $3.41B | $2.37B | $2.10B | $564.40M | $628.90M | $1.72B | $1.37B | $1.02B | $1.11B | $1.09B | $1.51B | $354.00M | $1.29B | $1.26B | $1.05B | $1.14B | $1.62B | $1.17B | $1.08B |
| QoQ Change | — | +444.7% | -30.5% | -11.4% | -73.1% | +11.4% | +173.5% | -20.5% | -25.2% | +9.0% | -2.2% | +38.8% | -76.6% | +264.7% | -2.2% | -17.2% | +9.5% | +41.4% | -27.7% | -7.8% |
| YoY Change | — | — | — | — | -9.9% | -81.6% | -27.5% | -34.9% | +81.1% | +77.2% | -36.6% | +10.6% | -65.4% | +15.9% | +15.9% | -30.9% | +223.3% | +25.4% | -7.3% | +3.2% |
Operating Cash Flow at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's operating cash flow?
- Regeneron Pharmaceuticals (REGN) reported operating cash flow of $1.08B in Q1 2026.
- How has Regeneron Pharmaceuticals's operating cash flow changed year-over-year?
- Regeneron Pharmaceuticals's operating cash flow increased by 3.2% year-over-year, from $1.05B to $1.08B.
- What is the long-term trend for Regeneron Pharmaceuticals's operating cash flow?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's operating cash flow has grown at a -8.4% compound annual growth rate (CAGR), from $7.08B to $4.98B.
- What does operating cash flow mean?
- The actual amount of cash a company brings in from its day-to-day business activities.